Feedback / Questions
tegavivint (BC2059) - Iterion Therap
https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-first-patient-dosed-in-clinical-study-of-tegavivint-a-first-in-class-wnt-catenin-inhibitor-in-relapsedrefractory-osteosarcoma-302683289.html
Feb 10, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next